Clinical Cardiology · 2012 · 10 citations · 25 references
MedicinePharmacologyPharmacotherapyHemodynamic ManagementPulmonary Function TestingPulmonologyInhalation Dosage FormsInhalation Drug DeliveryInhalation TherapyInhaled Medication AdministrationPulmonary HypertensionClinical Trial Efficacy EndpointsPrimary Efficacy EndpointsSecondary Efficacy Endpoints
Abstract Background: Inhaled iloprost (average >30 µg/d) has been considered an effective treatment for severe pulmonary hypertension (PH). Further evidence also showed that low‐dose iloprost given intravenously was equally effective as high‐dose iloprost in the therapy of systemic sclerosis. Hypothesis: Patients with pulmonary hypertension will benefit from inhalation of low‐dose iloprost. Methods: Sixty‐two patients with PH were enrolled and initiated with neubulizedlow‐dose iloprost (2.5 µg per inhalation, 6× daily) for 24 weeks in 13 medical centers in China. Efficacy endpoints included changes in 6‐minute walk distance (6MWD), World Health Organization functional class (WHO‐FC), and hemodynamic parameters. Results: Fourteen patients (22.6%) prematurely discontinued the study: 8 due to clinical worsening (6 in WHO‐FCIII–IV at baseline), 4 because of protocol change, and 2 patients lost during follow‐up. In the remaining 48 patients, 6MWD was increased from 356 ± 98 meters to 414 ± 99 meters ( P < 0.001) and WHO‐FC improved significantly ( P = 0.006) after 24‐week inhalation therapy. Cardiac output, cardiac index, and mixed venous oxygen saturation improved significantly compared with baseline (n = 34, P < 0.05). Most of the hemodynamic parameters improved significantly in patients in WHO‐FC II ( P < 0.05) but not in patients in WHO‐FCIII–IV. Conclusions: Low‐dose iloprost inhalation significantly improved exercise capacity and functional status in patients with PH. It was well tolerated. The improvement of hemodynamics was confirmed in patients with WHO‐FCI–II but not in patients with WHO‐FCIII–IV, suggesting the importance of early treatment in patients with advanced disease stages. Clin. Cardiol. 2012 DOI: 10.1002/clc.21987 This study was supported by National Grant from the Ministry of Science and Technology (Beijing, China, project number 2006BAI01A07) and the Capital Development Scientific Fund (Beijing, China, project number 2005‐1018). The authors have no other funding, financial relationships, or conflicts of interest to disclose.
25
Survival in Patients with Primary Pulmonary Hypertension
Gilbert E. D’Alonzo, Robyn J. Barst, Stephen M. Ayres et al. · Annals of Internal Medicine · 1991 · 3.5K citations
Bosentan Therapy for Pulmonary Arterial Hypertension
Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al. · New England Journal of Medicine · 2002 · 2.7K citations · Full text
Inhaled Iloprost for Severe Pulmonary Hypertension
Horst Olschewski, Gérald Simonneau, Nazzareno Galiè et al. · New England Journal of Medicine · 2002 · 1.8K citations · Full text